Working together to
promote the advance
of all aspects of
cancer research.

Clinical Research Fellow

  • Salary in the range of £30,302 - £47,647 per annum (depending on qualifications and experience)
  • Job Ref: MI/17/13
  • Duration: 4 Year fixed term contract

An outstanding opportunity has arisen for a Clinical Research Fellow to join the Manchester Melanoma Group at the Christie NHS Foundation Trust and the Molecular Oncology and Clinical and Experimental Pharmacology Groups at Cancer Research UK Manchester Institute. The aim of the project is to identify biomarkers of response and resistance to immunotherapies in melanoma and is intended to lead to peer reviewed publications and the award of a PhD.

Immunotherapy has revolutionised the treatment of metastatic melanoma and is having significant impact in other tumour types.  Approximately 40-45% of patients respond to single agent treatment (with immune checkpoint inhibitors anti-CTLA4, anti-PD-1, or anti-PD-L1) and 55% to combination treatment.  Together with targeted therapies, immunotherapy has contributed to increasing the expected median survival for patients with advanced melanoma from 9 months to 25-30 months. 

However, the mechanisms underlying primary and acquired resistance are multiple, complex and poorly understood. Even for patients responding to treatment, patterns of response and long term outcomes are variable. For this reason, it is imperative that clinical trials assessing immunotherapies include biomarker analyses over the course of treatment.

The Manchester Melanoma Group is working to understand the mechanisms underlying primary refractoriness to immunotherapies. These efforts involve the analysis of patient samples from patients on standard of care as well as on immunotherapy clinical trials. As part of these efforts, the group is planning two prospective, investigator-led studies to investigate: 1) the outcome of switching to combination immunotherapy in patients with disease that is primary refractory to single-agent immunotherapy and 2) a neo-adjuvant study of immunotherapy in patients with resectable mucosal melanoma.

The purpose of this PhD studentship is to lead on the development and co-ordination of the translational research aspects of the project and planned trials, to implement robust biomarker analysis to reveal the pathological and molecular mechanisms underlying primary resistance to immunotherapies, and to understand the clinical implications of the findings and how to use this information to improve patient care.

The successful applicant should have a MB, ChB (or equivalent) and hold Membership of the Royal College of Physicians (MRCP) (or equivalent) and General Medical Council (GMC) registration with license to practice medicine in the UK.

For any informal enquiries about this post, please contact Nathalie Dhomen, email:

The Cancer Research UK Manchester Institute (, an Institute of The University of Manchester (, is a world-leading centre for excellence in cancer research.  The Institute is core funded by Cancer Research UK (, the largest independent cancer research organisation in the world.  They are adjacent to The Christie NHS Foundation Trust (, one of the largest cancer treatment centres in Europe.  These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

To apply for this position and for further information please visit their website:


The deadline for receipt of applications is: 5th April 2017




Start Date

13th March 2017

Closing Date

5th April 2017